Exact Sciences Posts Record 2025 Revenue Amid Abbott Merger Push
Event summary
- Exact Sciences reported $878M in Q4 2025 revenue, up 23% YoY, and $3.25B for full-year 2025, up 18% YoY.
- Screening revenue grew 26% YoY to $695M in Q4, while Precision Oncology revenue increased 14% to $183M.
- Company launched three new tests in 2025, including Oncodetect for breast cancer and Oncoguard for liver cancer.
- Pending merger with Abbott Laboratories expected to close in Q2 2026, subject to regulatory approvals.
- Adjusted EBITDA was $63M in Q4, impacted by $75M R&D expense related to Freenome collaboration.
The big picture
Exact Sciences' strong 2025 performance underscores the growing demand for advanced cancer diagnostics. The pending Abbott merger signals a shift in the cancer screening landscape, with potential for expanded global reach. The company's focus on launching innovative tests positions it as a key player in personalized medicine, though integration challenges and regulatory hurdles remain.
What we're watching
- Merger Integration
- How Abbott will integrate Exact Sciences' portfolio and whether the combined entity can maintain Exact's growth trajectory.
- Regulatory Approvals
- The pace at which Exact Sciences secures FDA approvals for its new tests, particularly the Cancerguard multi-cancer detection test.
- Revenue Diversification
- Whether Exact Sciences can sustain growth in both screening and precision oncology segments post-merger.
Related topics